Relmada Therapeutics, Inc. (RLMD)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Relmada Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Relmada Therapeutics, Inc. (RLMD) has returned 44.10% so far this year and 2,477.78% over the past 12 months. Over the last ten years, RLMD has returned 0.23% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Oct 9, 2014, RLMD's average daily return is +0.19%, while the average monthly return is +3.40%. At this rate, your investment would double in approximately 1.7 years.

Historically, 49% of months were positive and 51% were negative. The best month was Oct 2019 with a return of +173.2%, while the worst month was Dec 2024 at -82.8%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 7 months.

On a daily basis, RLMD closed higher 43% of trading days. The best single day was Oct 15, 2019 with a return of +134.0%, while the worst single day was Oct 13, 2022 at -79.6%.

Relmada Therapeutics, Inc. has an annualized alpha of 45.31%, beta of 0.76, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since October 10, 2014.

• This stock participated in 127.31% of S&P 500 Index downside but only 6.84% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RLMD ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Relmada Therapeutics, Inc. (RLMD) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Relmada Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Relmada Therapeutics, Inc. was 99.66%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Relmada Therapeutics, Inc. drawdown is 90.65%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Relmada Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Relmada Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.